The estimated Net Worth of David N Cook is at least $2.93 Milhão dollars as of 23 February 2022. Dr Cook owns over 3,531 units of Forma Therapeutics stock worth over $329,545 and over the last 21 years he sold FMTX stock worth over $2,597,173.
Dr has made over 5 trades of the Forma Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 3,531 units of FMTX stock worth $34,533 on 23 February 2022.
The largest trade he's ever made was selling 61,000 units of Forma Therapeutics stock on 1 April 2016 worth over $1,595,760. On average, Dr trades about 4,197 units every 94 days since 2003. As of 23 February 2022 he still owns at least 16,469 units of Forma Therapeutics stock.
You can see the complete history of Dr Cook stock trades at the bottom of the page.
Dr. David N. Cook Ph.D. is the Sr. VP & Chief Scientific Officer at Forma Therapeutics.
Dr D is 63, he's been the Sr. VP & Chief Scientific Officer of Forma Therapeutics since . There are no older and 7 younger executives at Forma Therapeutics.
David's mailing address filed with the SEC is C/O FORMA THERAPEUTICS HOLDINGS, INC., 300 NORTH BEACON STREET, SUITE 501, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Forma Therapeutics have traded over $446,330 worth of Forma Therapeutics stock and bought 9,000,000 units worth $180,000,000 . The most active insiders traders include Capital Management, L.P.Ra ..., Peter Kolchinsky, eCapital Management, L.P.Ra .... On average, Forma Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $10,575,905. The most recent stock trade was executed by Patrick F. Kelly on 13 April 2022, trading 15,000 units of FMTX stock currently worth $75,750.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Forma Therapeutics executives and other stock owners filed with the SEC include: